Loading...
01/10 16:25
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
Revenue Second quarter revenue of $120 million, representing a year-over-year growth of more than 20%. This growth was driven by monthly records in the pharmacy business and 10% year-over-year growth in the fee-for-service business, particularly in Florida and Oregon.
Adjusted EBITDA Adjusted EBITDA loss of $4.1 million in Q2, which is a $4.6 million improvement compared to the same quarter last year. This reduction in loss was primarily due to organic fee-for-service and pharmacy revenue growth, disciplined clinical payroll and SG&A management, and improved drug margins.
Pharmacy Revenue Pharmacy revenue of $62.6 million in Q2, a 41% increase compared to Q2 of last year and a 27% sequential increase. This growth was driven by increased patient volumes, reduced prescription leakage, and operational discipline.
Gross Profit Gross profit of $17.5 million in Q2, a 34% year-over-year increase. Gross margin improved by 140 basis points year-over-year to 14.6%, driven by better dispensary gross margins, though partially offset by a slight decline in patient services gross margin.
SG&A Expenses SG&A expenses of $26.9 million in Q2, a 3.5% decrease from the same period last year. Normalizing for a $2.4 million one-time write-off, SG&A would have decreased 12% year-over-year, reflecting operational leverage and cost discipline.
Cash Flow Cash flow from operations for the first half of 2025 was a loss of $15.2 million, a 52% improvement from the first half of 2024. Free cash flow was negative $14.6 million for the first 6 months, a 54.1% reduction from the same period last year.
Pharmacy Business Growth: Achieved over 40% growth in Q2 2025 compared to Q2 2024, driven by increased patient volumes and reduced prescription leakage. Forecasting over 35% growth for the full year.
AI Enablement Initiatives: Launching three AI initiatives in Q3 2025 to improve revenue cycle management, prior authorization services, and patient call center operations.
Capitated Contracts Expansion: Added over 50,000 capitated lives in Nevada and California in Q2 2025. Expanded capitation relationship with Silver Summit Health Plan in Nevada, adding 49,000 Medicaid patient lives. Reached a verbal agreement to expand a partnership in Florida, adding over 40,000 Medicare Advantage lives in Q4 2025.
Geographic Expansion: Focused on expanding capitated relationships and partnerships in nearly every market where TOI operates.
Revenue Growth: Achieved 21.5% year-over-year revenue growth in Q2 2025, reaching $119.8 million. Pharmacy revenue grew 41%, and patient services revenue grew 7%.
Cost Management: Reduced SG&A expenses by 12% year-over-year, representing 22% of total revenue in Q2 2025. Improved drug margins through strategic purchasing and formulary management.
Leadership Changes: Appointed Kristin England as Chief Administrative Officer to oversee business operations and technology strategy. Anne McGeorge elected as new Chair of the Board.
Technology and AI Strategy: Focused on transforming into a technology and AI-enabled care delivery organization to improve patient and physician experience while reducing operational expenses.
Regulatory and Compliance Risks: The company acknowledges risks and uncertainties related to forward-looking statements and guidance, which could cause actual results to differ materially. This includes potential regulatory hurdles and compliance challenges.
Financial Performance Risks: Despite improvements, the company reported an adjusted EBITDA loss of $4.1 million in Q2 2025. Achieving positive adjusted EBITDA by Q4 remains a challenge, with risks tied to revenue growth, cost management, and operational efficiencies.
Capitation Contract Risks: New capitation contracts tend to experience lower margins initially as the company works to operationalize and mature these contracts. This could impact short-term profitability.
Pharmacy Business Risks: The company is heavily reliant on its pharmacy business, which experienced significant growth. However, this growth increases accounts receivable and rebate AR, creating cash flow management challenges.
Supply Chain and Drug Cost Risks: Rising drug costs and reliance on strategic purchasing and formulary management pose risks. Delays in rebate payments from manufacturers could also impact cash flow.
Operational and Technological Risks: The company is launching AI enablement efforts to improve cost efficiency and operational performance. However, the success of these initiatives is uncertain and could impact operational outcomes.
Leadership Transition Risks: The retirement of the current Chairman and the appointment of a new Chair could create transitional challenges and impact strategic decision-making.
Revenue Expectations: The company expects full-year 2025 revenue to be in the range of $460 million to $480 million, with a strong belief in reaching the high end of this range due to growth in the first half of the year.
Adjusted EBITDA: The company anticipates adjusted EBITDA for 2025 to range from a loss of $17 million to a loss of $8 million, with a solid line of sight to the midpoint of this range. Positive adjusted EBITDA is expected in Q4 2025.
Pharmacy Business Growth: The pharmacy business is forecasted to grow over 35% for the full year compared to the prior year, driven by increased patient volumes and reduced prescription leakage. An additional pharmacy location in Florida is expected to open in the second half of 2025.
Capitated Partnerships: The company plans to expand capitated partnerships, including a new contract in Florida starting in Q4 2025, which will add over 40,000 Medicare Advantage lives. This expansion will double the current relationship with the payer and bring total Medicare Advantage lives under capitation in Florida to over 100,000.
Gross Margin Improvement: Sequential improvement in gross margin is anticipated in the second half of 2025, driven by optimization of risk margins, drug pricing spread expansion, and supply chain and formulary management.
AI Enablement: The company is launching three AI initiatives in Q3 2025 to improve performance and reduce costs in revenue cycle management, prior authorization services, and the patient call center.
The selected topic was not discussed during the call.
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
The earnings call reveals strong financial performance with a 44% increase in gross profit and improved EBITDA, indicating operational efficiency. The company has a robust pipeline, especially in fee-for-service revenue, and is on track for cash flow positivity by Q4 2025. Despite some uncertainties in contract terminations, the overall guidance is optimistic, with significant revenue growth expected. The positive sentiment is further supported by improved margins and cost optimization efforts, suggesting a favorable short-term stock price movement.
The earnings call summary indicates strong financial performance with 21% revenue growth, improved gross profit, and reduced losses. New contracts and cost optimization strategies further strengthen the outlook. Although there are some risks in contractual stability and financial performance, management appears confident in their ability to mitigate these. The Q&A section did not reveal significant negative trends. Overall, the positive financial results and guidance, alongside operational improvements and a commitment to shareholder value, suggest a positive stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
